H19-Promoter-Targeted Therapy Combined with Gemcitabine in the Treatment of Pancreatic Cancer
Figure 1
Sequential administration of BC-819 and gemcitabine in a hamster orthotopic pancreatic carcinoma model. (a) Average of ex vivo tumor volume of the nontreated, gemcitabine, and BC-819 + gemcitabine treated groups measured after sacrifice (day 18). Asterisks indicate significant difference after BC-819 + gemcitabine compared with no treatment or gemcitabine alone (*, **, and ***). (b) Average of tumor growth progression of the nontreated, gemcitabine, and BC-819 + gemcitabine treated groups calculated as the ratio of tumor size at the end of the experiment (day 18) compared to the size before treatment (day 7).